Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S S Bielack

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
British Journal of Cancer|June 30, 2012
Comment on: 'Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?'S S Bielack
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2008
State-of-the-art approach in selective curable tumors: bone sarcomaS S Bielack, D Carrle
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
OsteosarcomaJ Ritter, S S Bielack
ESMO Open|December 23, 2021
A special jubilee: 100 fake osteosarcoma articlesS S Bielack, E Palmerini
Cancer|August 1, 1997
Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literatureS S Bielack, G Beron, K Winkler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrenceS S Bielack, B Kempf-Bielack, K Winkler
Cancer Treatment and Research|January 1, 1993
Intraarterial chemotherapy for osteosarcoma: does the result really justify the effort?S S Bielack, P Bieling, R Erttmann, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1989
Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacyS S Bielack, R Erttmann, K Winkler, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 1996
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?S S Bielack, R Erttmann, B Kempf-Bielack, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2006
Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System projectC A Stiller, S S Bielack, G Jundt, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|June 30, 2012
Comment on: 'Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?'S S Bielack
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2008
State-of-the-art approach in selective curable tumors: bone sarcomaS S Bielack, D Carrle
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
OsteosarcomaJ Ritter, S S Bielack
ESMO Open|December 23, 2021
A special jubilee: 100 fake osteosarcoma articlesS S Bielack, E Palmerini
Cancer|August 1, 1997
Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literatureS S Bielack, G Beron, K Winkler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrenceS S Bielack, B Kempf-Bielack, K Winkler
Cancer Treatment and Research|January 1, 1993
Intraarterial chemotherapy for osteosarcoma: does the result really justify the effort?S S Bielack, P Bieling, R Erttmann, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1989
Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacyS S Bielack, R Erttmann, K Winkler, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 1996
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?S S Bielack, R Erttmann, B Kempf-Bielack, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2006
Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System projectC A Stiller, S S Bielack, G Jundt, et al.
Pageof 3